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Abstract The human 5-HT,, serotonin receptor has been cloned. As with the mouse and rat 5-HT,, receptors, the gene consists of two coding exons 
separated by a large intron. The deduced amino acid sequence of the gene reveals a protein of 357 residues which shares 93% (nucleotide) and 84% 
(amino acid) identity to the cloned mouse 5-HT,, receptor. We have determined the tissue distribution of the receptor by reverse transcriptase-PCR 
and found expression in all regions of the brain examined with little or no expression in peripheral tissues. The receptor has been transiently expressed 
in Cos M6 cells and exhibits a pharmacological profile closely resembling the mouse and rat 5-HT,, receptors with high, specific binding for 
ergotamine and methiothepin. 
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1. Introduction 
The neurotransmitter 5-hydroxytryptamine (5HT; sero- 
tonin) modulates a wide range of physiological and pathologi- 
cal processes in the central nervous system and periphery, 
including anxiety, sleep regulation, aggression, feeding and 
depression [l]. Both pharmacological characterisation and, 
more recently, molecular cloning of several 5-HT receptor 
genes has revealed that 5-HT mediates its diverse physiological 
actions through a multiplicity of receptor subtypes [2]. These 
receptors belong to at least two different protein superfamilies; 
ligand- gated ion channel receptors (5-HT,) and the G protein- 
coupled 7-transmembrane receptor superfamily (thirteen dis- 
tinct receptors cloned to date) [l]. In addition, within the G 
protein-coupled 7-transmembrane receptor superfamily, sero- 
tonin exerts its actions through a multiplicity of signal 
transduction mechanisms; for example, in recombinant systems 
the 5-HT,, receptor has been demonstrated to couple to inhibi- 
tion of adenylate cyclase, generation of inositol phosphate, and 
to an inward rectifying potassium channel [l]. 
Recently two members of a new subfamily of serotonin re- 
ceptors has been identified. These have been cloned from 
mouse and rat and designated 5-HTSA and 5-HTsB [2-51. The 
two mouse receptors share 77% amino acid homology [2]. By 
pharmacological criteria these receptors fall into the 5-HT,-like 
class because of their antagonism by methiothepin and agonism 
by 5-carboxytryptamine [l]. However, there are several reasons 
why these receptors have been placed in a distinct class. The 
sequence is not closely related to that of any previously known 
serotonin receptor, with the best homology being 41% with the 
Drosophila 5HT,,, receptor [6] and less than 37% to members 
of the 5-HT, family [l]. Additionally the mouse and rat 5-HTs 
genes have an intron between putative transmembrane domain 
V and VI, in contrast with the 5-HT, receptor genes which are 
intronless [l]. Unlike the 5-HT, family of receptors, which all 
show negative coupling to adenylate cyclase through an inhib- 
itory G protein signal transduction complex [ 11, expression of 
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5-HT,, receptors in recombinant mammalian cell lines has 
failed to demonstrate any G protein coupling [2,3,5], suggesting 
that these receptors may have a novel signal transduction mech- 
anism. There is a single report of coupling to the rat 5-HTSB 
receptor to a G protein in COSl cells, although the nature of 
the second messenger response is unclear [4]. Similarly there are 
no known functional correlates of 5-HTS receptor activation, 
although it appears likely that they may perform some func- 
tions within the CNS previously attributed to the 5-HT,n fam- 
ily, such as motor control, feeding and anxiety [1,2]. 
In order to investigate further the role of this novel receptor 
subfamily we have cloned the human 5-HT5* serotonin recep- 
tor. We present an analysis of the pattern of expression of the 
receptor and an initial pharmacological characterisation. 
2. Experimental 
2.1. Isolation of genomic clones 
A 378 bp fragment of human 5-HT,, was amplified, from genomic 
DNA, using the polymerase chain reaction (PCR) with degenerate 
oligonucleotide primers, S-cT(GIC)CroGTcGc(T/C)CiT(G~- 
CTGGT(T/G)ATGCCJ and 5’.AG(GIA)TAGAAGGC(AiT)CC(Al 
C/G/T)(A/C)(A/C)GGTGGA(A/G)AA-3’, designed from an alignment 
of the mouse 5-HT,, and 5-HTSB receptor sequences [3]. This fragment 
of 5-HT,, spans putative transmembrane domains II-V and represents 
part of exon 1 of the gene. The PCR product was subcloned into 
pcDNA1 (Invitrogen) and its sequence was found to be 92% identical 
to mouse 5-HT,, over this region [3]. The rat 5-HT,, cDNA was 
obtained from Dr. M. Voight [5l. 
The 378 bp human 5-HT,, fragment and the rat 5-HT, cDNA were 
labelled with [a-‘2P]dCTP (Amersham) by random priming (Strat- 
agene) and used to screen a HepG2 human liver cell line genomic library 
constructed in L-FIX (Stratagene). Filter lifts were made onto Hybond- 
N membrane (Amersham) and hybridisation performed at 60°C for 
16 h in 10% dextran sulphate, 1 M NaCl, 1% sodium dodecyl sulphate 
(SDS). Filters were then washed at 60°C in 1 x SSC, 0.1% SDS. Seven 
positive clones were detected from 4 x lo6 independent plaques. The 
inserts were character&d by restriction analysis followed by Southern 
blotting, and small hybridising fragments ubcloned into pBluescript 
(Stratagene). 
2.2. Sequencing 
Sequence analysis was performed directly on double-stranded plas- 
mid DNA using the Sequenase Version 2.0 DNA sequencing kit [7j 
(USB). Sequence diting, alignment and comparisons were performed 
with the Genetics Computer Group software (University of Wisconsin). 
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2.3. Construction of a fill-length clone 
Exon 1 was found to lie on a 4.1 kb EcoRI-HindI restriction 
fragment and exon 2 on a 1 .O kb EcoRI fragment. No single phage was 
isolated containing both exons. To verify that the two exons represent 
the same gene, oligonucleotide primers F’CRl (5’-ACI’Cl’CCGCTG- 
TCATCTCTCTGGJ’), designed from the exon 1 sequence, and PCR2 
(5’-TGGCGTGGCGGACCGTGAACAGG-3’), designed from the 
exon 2 sequence (see Fig. 2), were used to amplify a 293 bp fragment 
by PCR from human hippocampus cDNA (Clonteoh). The sequence of 
this fragment agreed exactly with the genomic sequence obtained previ- 
ously, eonflrming the two exons to be the same gene, the gene to be 
expressed and the precise position of the intron/exon boundary. 
ln order to join the twdexons together, exon 1 was amplified from 
the xenomic fragment bv PCR usina mimers 5’-TGACGAATTCAT- 
GG~T’lTACC/iGTGtiCCC~-3’ and S-CCCACGTCGACA- 
GCTTCGGATATGGGTGAG-3’, and the resulting product was di- 
gested with EcoRI and SalI. Exon 2 was similarly amplifted using 
primers 5’CTTTTCTCGAGGTGAACGACTCTGCCAACJ’ and 
5’-TGGTGAATTCCCTCAGTGTTGCCTAGAAAAG-3’, and the 
PCR product digested with XhoI and EcoRI. The two products were 
ligated and subcloned into the EcoRI site of the expression vector 
pcDNA4 (a derivation of pcDNA3 (Invitrogen) containing a synthetic 
intron [S] in the multiple cloning site). The open reading frame was 
re-sequenced following PCR. 
2.4. Cell culture and homogenate preparation 
Cos M6 cells maintained at 37°C with 5% COZ and 92% humidity, 
in Dulbecco’s modified Eagle’s medium, supplemented with 10% foetal 
calf serum, 1% glutamine and 1% non-essential amino acids (all rea- 
gents from Gibco), were transfected with the pcDNA4/5-HT, expres- 
sion vector using the DEAE Dextran procedure 191. Two days post- 
transfection, cells were detached by incubation in phosphate buffered 
saline (PBS) containing 5 mM EDTA and harvested by centrifugation 
at 4500 x g for 35 min (Sorvall RC3). The cell pellet was re-suspended 
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in assay buffer (100 mM Tris-HCl, 1 mM EDTA and 1% ascorbic acid, 
pH 7.7) and counted before homogenisation (Ultraturax). Homoge- 
nates were diluted in assay buffer to yield a concentration of 1 x 10’ 
cells/ml. 
2.5. Radioligand binding assay 
The following conditions were used for radioligand binding: cell 
homogenate (750 pl), [‘H]S-CT (1 .O nM final concentration, 200~1) and 
competing drug or assay buffer (50 ~1) were incubated at 37°C for 30 
min. Incubations were terminated by rapid filtration (Tomtee; 48 well 
harvester) through printed Filtermat B filters pre-soaked in 0.1% PEI 
(polyethyleneimine) for 1 h. The filters were washed four times with 
1 ml ice-cold assay buffer. Retained radioactivity was measured (1204 
Betaplate BS solid scintillation counter) after melting the dried filters 
into solid scintillation wax. Under these conditions, specific [HIS-CT 
binding (defined by inclusion of 10 PM 5-CT) represented greater than 
90% of total binding. Competition and ligand binding data were analy- 
sed by using non-linear curve fitting techniques (RSl, Radlig). 
2.6. Drugs used 
5-Hydroxytryptamine creatinine sulphate (Sigma), methysergide hy- 
drogen-maleate (Sandoz), yohimbine hydrochloride (Sigma), ergotam- 
ine tartrate (Sigma), (-)pronranolol-HCl (Sigma). RU 24969 (Roussel ,_ 
Uclaf), 8-hy~dr~xydipropyl&inotetralin ‘@BI); ‘metergoline (Farmi- 
talia), ketanserin (Sigma) and [3HJ5-oarboxyamidotryptamine (NEN- 
DuPont). 5-Carboxyamidotryptamine maleate, methiothepin maleate, 
zacopride and sumatriptan were synthesised by the Chemistry Research 
Department at Glaxo Research & Development. All drugs used were 
initially dissolved in a mixture of pure DMSO and 1 M HCl (5: 1). 
Further dilution’s were performed in assay buffer. 
2.7. Tiisue distribution 
Reverse transoriptase-PCR (RT-PCR) was performed using the 
GeneAmp RNA F’CR kit (Perk&Elmer) on 100 ng of human poly(A)+ 
1 
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KLCQLWIACDVLCCTASIWNVTAIALDKYWSIT 
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740 
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Fig. 1. Nucleotide and deduced amino acid sequence of the human 5-HT,, gene. Exon sequence is in upper case; intron and flanking sequence in 
lower case. The seven putative transmembrane domains of the receptor are underlined and numbered I to VII. Three stop codons, one in each frame, 
upstream of the start codon are in bold type. The position of PCR primers 1 and two (sea section 2) are indicated with arrows. 
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RNA (Clontech) with primers PCRl and PCR2 (Fig. l), which span 
the 5-HT, intron, amplifying 293 bp from mRNA and 15 kb from 
genomic DNA. PCR products were separated by agarose gel electro- 
phoresis and blotted onto Hybond-N membrane (Amersham) prior to 
hybridisation with a ‘*P-labelled human 5-HT,, gene probe. 
3.2. Expression and pharmacological characterisation of the 
human 5-HT,, receptor 
The two exons were joined together, using a PCR strategy, 
to produce a single open reading frame, which was cloned into 
the expression vector pcDNA4. The ligand binding characteris- 
tics of the receptor were investigated with the ligand [‘MS-CT 
following transient transfection of the 5-HT,* expression vec- 
tor into Cos M6 cells. Over a range of ligand concentrations 
(0.2-14 nM), specific binding was observed. Non-specific bind- 
ing increased linearly with ligand concentration. Scatchard 
analysis of the specific binding data revealed a single site wth 
a Ku value of 4.0 nM and B,, of 241 fmol/mg (data not shown). 
A ligand concentration of 1 nM was used in all displacement 
experiments. The binding affinity constants (pfi) for the com- 
petition curves of various ligands are given in Table 1. 
3.Results 
3.1. Cloning of human 5-HT, genomic sequences 
A 378bp fragment of human 5-HT,,, spanmng putative 
transmembrane domains II-V, together with the rat 5-HTsB 
cDNA, was radiolabelled and used as a hybridisation probe to 
screen a human genomic library for 5-HT,-like sequences. 
Seven strongly hybridising clones were isolated and character- 
ised by restriction analysis followed by Southern blotting and 
hybridisation with single exon probes. These studies revealed 
no clone that contained both exons. However, small hybridising 
fragments of each il phage insert were subcloned and se- 
quenced. A single clone contained a 741 bp open reading frame 
which shows 83% homology to exon 1 of mouse 5-HT,,; a 
further two clones contained a 333 bp open reading frame with 
85% homology to exon 2 of mouse 5-I-IT,, (see Fig. 1) [3]. The 
site of the intron/exon boundary is in an identical position to 
that in the mouse 5-HT,, gene [3]. To con&m that these clones 
represent wo exons of the same gene, PCR primers were de- 
signed flanking the site of the putative intron. RT-PCR analysis 
of human hippocampus cDNA resulted in the amplification of 
the expected 293 bp RNA-specific fragment, which was se- 
quenced and shown to be identical to the cloned human 5-HTSA 
gene (data not presented). This confirms the position of the 
junction between exons 1 and 2. From restriction analysis of 
the original L phage the intron appears to be at least 5 kb long. 
The start codon was assigned according to homology with 
mouse 5-HT,,. There are three alternative stop codons, one in 
each frame, 5’ to this start codon (see Fig. l), suggesting that 
the assigned ATG is correct. 
Table 1 
Comparison of the pharmacological profile of the human and mouse 
5-HT,, serotonin recenters 
pKi values 
Human Mouse 
5-HT 6.9 (8) 6.6 (7) 
5-CT 7.7 (7) 7.8 (3) 
Ergotamine 8.7 (5) 8.4 (2) 
Sumatriptan 5.3 (5) 4.8 (2) 
Methiothepin 8.9 (3) 7.0 (2) 
Methysergide 7.0 (4) 7.2 (5) 
Ketanserin 4.7 (3) 4.8 (2) 
Metergoline 6.2 (3) - 
Yohimbine 5.3 (3) 6.0 (2) 
(-)Propranolol 5.1 (3) 4.7 (2) 
RU 24969 6.0 (3) 6.5 (2) 
8-OHDPAT 5.6 (5) 5.9 (2) 
Clozapine 6.0 (4) - 
Zacopride 
Spiperone z ;; - 
Pindolol 4:9 (3) 1 
Melatonin < 4 (2) 
Noradrenaline < 4 (2) 
Numbers in parenthesis correspond to the number of independent ex- 
periments with each point measured in duplicate. Human studies were 
performed with [‘H]5-cT, mouse studies with [‘*‘I]LSD [12]. 
3.3. Tissue distribution analysis of human SHT,, receptor 
expression 
The pattern of expression of the human 5-HT,, serotonin 
receptor was determined by RT-PCR using oligonucleotides 
PCRl and PCR2 (Fig. 1). The 293 bp RNA specific product 
was amplified from every brain tissue examined (amygdala, 
caudate nucleus, cerebellum, hypothalamus, substantia nigra 
and thalamus; Fig. 2). A weaker signal was detected in fetal 
brain. Expression was not seen in any peripheral tissue (aorta, 
heart, kidney, liver, small intestine, spleen and uterus). This 
pattern of expression is similar to that seen in mouse and rat 
[3,4] and suggests a role for 5-HT,, in CNS function. 
4. Discussion 
We have cloned the human 5-HTSA serotonin receptor from 
genomic DNA. The gene consists of two exons separated by a 
large intron positioned in the third intracellular loop of the 
deduced amino acid sequence. Removal of the intron creates 
a 1071 bp open reading frame which would encode a 357 amino 
acid protein, the same length as the rat and mouse 5-HT,, 
receptors [3,4]. Hydropathy analysis indicates this protein to 
posess seven hydrophobic transmembrane domains (data not 
shown), as expected for a G protein-coupled receptor [lo]. The 
cloned human 5-HTTA receptor posesses 93% (nucleotide) and 
84% (amino acid) homology with the cloned mouse 5-HTsA 
receptor, and only 71% (nucleotide) homology to the mouse 
5-HTsB receptor [3], providing further evidence that this gene 
encodes the human 5-HT5* serotonin receptor. 
In the course of our studies we isolated five clones from the 
HepG2 genomic library which contained an identical 182 bp 
sequence which shows 93% nucleotide identity to part of exon 
2 of mouse 5-HT,, (data not shown) [3]. We believe this to 
represent part of the human 5-HTSB gene; however, despite 
extensive studies we have been unable to isolate the putative 
exon 1 of this gene. In addition we have failed to demonstrate 
expression of this sequence in brain cDNA. These studies indi- 
cate that a functional 5-HT,, receptor may not exist in humans; 
if so, this would represent the first example of a serotonin 
receptor isolated in other species but not found in man. 
We have expressed the human 5-HT5* serotonin receptor in 
Cos M6 cells and have determined the ligand binding character- 
istics of this receptor (Table 1). These values show good agree- 
ment with afiinity constants derived from studies on the cloned 
rat and mouse 5-HTs, receptors [2,4], with the exception of 
S. Rees et al. IFEBS Letters 355 (1994) 242-246 
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Fig. 2. Reverse transcriptase-PCR analysis of the pattern of expression ofRNA encoding the uman 5-HT,, receptor (see section 2for details). DNA 
fragment sizes are indicated. 
methiothepin which shows a 60 fold higher affinity at the 
human receptor. This represents a novel pharmacology not 
shared with any other cloned human serotonin receptor [l]. 
The pattern of expression of the receptor was examined by 
RT-PCR. The receptor appears to be expressed exclusively in 
the adult brain with a lower level of expression in fetal brain. 
This may indicate that the receptor is developmentally, regu- 
lated with expression appearing at, or near, birth. We were 
unable to detect expression in any of the peripheral tissues 
examined. This pattern of expression is shared with the mouse 
and rat S-HT, receptors [24. We believe the level of expres- 
sion of this receptor to be low. In previous studies we were 
unable to isolate the 5-HT5* cDNA from either hippocampal 
or hypothalamic cDNA libraries. 
Expression studies with the mouse and rat 5-HT5* receptors 
have failed to detect functional coupling of the receptor to any 
second messenger pathway [24]. This may be due to the ab- 
sence of the appropriate G protein in the cell lines used, or may 
indicate that this receptor couples to a novel signal transduc- 
tion mechanism such as ion channels. The construction of a 
number of stable cell lines constitutively expressing the 5-HT,, 
receptor will facilitate the identification of the signal transduc- 
tion mechanism, particularly through expression of the recep- 
tor in neuronal cell lines. It remains possible that neuronal cells 
possess novel G proteins and signal transduction mechanisms, 
thus cell expression studies, usually performed in epithelial or 
fibroblast cell lines, may not reveal the true in vivo situation. 
The role of this receptor in normal CNS function and its 
possible involvement in a pathological state also remain un- 
known. Studies such as immunohistochemistry and in situ hy- 
bridisation would allow an identification of the cell types ex- 
pressing this receptor. However, the identification of a selective 
ligand, which could be used as a probe in in vitro experiments 
on various CNS tissues, would allow an examination of func- 
tional correlates of receptor activation. Such a ligand could also 
be used in in vivo behavioural studies to provide a definition 
of the physiological role of this receptor. 
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